此前拆过很多关于宜明昂科的核心管线——IMM01的细节，这款靶向CD47的融合蛋白解决了溶血问题后，为宜明昂科带来了非常高的热度。具体关于该靶点可以见文章《牛市创新药弹性第一股》。宜明昂科和康方都在针对CD47这个靶点苦下功夫，目的是为了让巨噬细胞配 ...

DS-3939 is designed using Daiichi Sankyo’s proprietary DXd ADC technology, which employs a combination of tetrapeptide-based cleavable linkers and topoisomerase I inhibitor payloads to deliver ...

ADC is considered a core technology for next-generation cancer drugs that selectively deliver drugs only to cancer cells. It consists of three connected elements: antibody, payload, and linker ...

The ADC targets 5T4, an oncofetal antigen expressed in a broad range of solid tumors. The program was developed using Tubulis’ proprietary Tubutecan linker-payload platform, which enables ...

via tetrapeptide-based cleavable linkers. About the ADC Portfolio of Daiichi Sankyo The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC ...